Skip to main content
TipRanks
Go Ultimate75% OFF

Annexon Biosciences (ANNX) Q2 2026 Earnings Report

1,429 Followers

ANNX Q2 2026 EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.24
Beat/Miss
Missed by -$0.04
One Year Ago EPS
-$0.34

ANNX Q2 2026 Revenue Results

Actual Revenue
$0
Expected Revenue
$0
Beat/Miss
Met expectations
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q2 2026
Date
08/12/2026
Time
Before Open
Conference Call
Wednesday, August 12, 2026
ANNX Upcoming Earnings

Annexon Biosciences's next earnings date is estimated for March 8, 2027, based on past reporting schedules.

Q2 2026 Earnings Call Audio

ANNX Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 12, 2026|% Change Since:-36.14%|
Earnings Call Sentiment|Positive

The call conveyed strong clinical and operational momentum: first-in-class pivotal GBS data with regulatory filings progressing, robust ARCHER II execution (659 enrolled, >95% dosing compliance, <10% discontinuation) and a strategic expansion to a month 24 dual primary endpoint that management says is well powered (>90%). Financial flexibility was improved with up to $200M in non-dilutive capital. Primary risks noted include the requirement to split alpha between month 15 and month 24 (undisclosed allocation), potential DMC-driven continuation or futility decisions that could delay readouts, and the introduction of debt obligations. Overall, the highlights — compelling clinical results, regulatory progress, strong trial execution and extended runway — materially outweigh the risks presented.

Company Guidance

On the Aug. 12, 2026 call (FY2026, Period 2) Annexon provided concrete timelines and metrics: it plans a U.S. BLA filing for tanruprubart in Q4 2026 while the EMA review continues, and reported FORWARD’s first 10‑patient cohort (single 30 mg/kg infusion) showed 10/10 rapid improvements (many within 48 hours, 4 bed‑bound patients walking by days 2–8, one ventilated patient weaned in 4 days), consistent with ~90% responders by week 1 in Phase III; GBS prevalence was cited as ~22,000/year in the U.S./EU (~150,000 worldwide) with U.S. annual healthcare burden >$20B and 1‑year mortality up to 10% (≈25% for >65). For GA, ARCHER II enrolled 659 patients (30 over target), has >95% dosing compliance, <10% discontinuation, all eligible patients ≥12 months on treatment, masked event accruals tracking to plan, a month‑15 DMC assessment expected Q4 2026 (base case positive), an added month‑24 dual primary endpoint with overall powering >90% for both time points, substudy results targeted Q1 2027 and study completion Q3 2027; vonaprument holds FDA Fast Track and EMA PRIME, an OLE is open post‑month 24, and the company secured up to $200M in non‑dilutive financing extending cash runway into 2028.

  • Positive Pivotal GBS Data and ReproducibilityTanruprubart showed reproducible, rapid clinical benefit: ~90% of treated patients responded by week 1 in the Phase III study, and all 10 patients in the initial FORWARD cohort improved rapidly. Notable outcomes included 4 previously bed-bound patients regaining ability to walk between days 2–8, one mechanically ventilated patient weaned within 4 days, and 5 patients with marked improvement within 48 hours. Safety was generally well tolerated and consistent with prior Phase III results.
  • Regulatory Progress for GBS (Europe & U.S.)Marketing Authorization Application is under review by EMA; U.S. Biologics License Application (BLA) for tanruprubart is on track for submission in Q4 2026, with FORWARD data planned to be included to support the filing.
  • ARCHER II Enrollment and Trial Execution StrengthARCHER II enrolled 659 patients (30 patients over original target), achieved dosing compliance >95% and patient discontinuation rate <10% (single-digit), and masked event accruals are tracking in line with projections — indicators of strong trial conduct and data robustness.
  • Phase III Statistical Power and Dual Primary EndpointThe study is highly powered (stated >90%) for both month 15 (base-case readout expected Q4 2026) and the newly added month 24 dual primary endpoint, enabling evaluation of longer-term benefit without operational changes to the masked 24-month trial.
  • ARCHER II Timeline and Regulatory DesignationsDMC assessment of month 15 is expected in Q4 2026; planned substudy analyses results expected Q1 2027; study completion expected Q3 2027. Vonaprument has FDA Fast Track and EMA PRIME designations and participation in EMA product development coordinator pilot, enabling enhanced regulator engagement.
  • Financial Strengthening — Non-Dilutive CapitalAnnounced a credit facility with Oxford Finance providing access to up to $200 million in non-dilutive capital, extending cash runway into 2028 and increasing financial flexibility for near- and long-term plans.
  • Clinical and Commercial Platform ProgressAnnexon highlights multiple platform achievements: first randomized placebo-controlled GBS pivotal data, the potential first vision-sparing therapy for GA, and an oral small molecule program targeting the classical complement pathway — supported by recent board and talent additions.

ANNX Earnings History

ANNX earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 08, 20272026 (Q4)-0.26--0.28――
Nov 09, 20262026 (Q3)-0.28-0.25-0.3732.43% (+0.12)
Aug 12, 20262026 (Q2)-0.24-0.28-0.3417.65% (+0.06)
May 07, 20262026 (Q1)-0.28-0.23-0.3737.84% (+0.14)
Mar 30, 20262025 (Q4)-0.31-0.28-0.3315.15% (+0.05)
Nov 10, 20252025 (Q3)-0.34-0.37-0.25-48.00% (-0.12)
Aug 14, 20252025 (Q2)-0.37-0.34-0.23-47.83% (-0.11)
May 12, 20252025 (Q1)-0.30-0.37-0.21-76.19% (-0.16)
Mar 03, 20252024 (Q4)-0.27-0.33-0.368.33% (+0.03)
Nov 14, 20242024 (Q3)-0.26-0.25-0.4341.86% (+0.18)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed